<DOC>
	<DOCNO>NCT00850707</DOCNO>
	<brief_summary>The aim present study investigate patient free active infection and/or thrombosis ass type vascular access ( AVF , AVG , TCC ) , could influence : 1. level serological marker inflammation ( CRP , IL-6 , TNF-a ) ; 2. degree expression monocyte surface inflammation immune response modulate molecule : CD14 , CD32 CD44 . 3. amount monocytic cell express senescent phenotype ( CD14 CD32 ) .</brief_summary>
	<brief_title>Vascular Access Hemodialysis Inflammation</brief_title>
	<detailed_description>Patients AVF assume ticlopidine 250 mg/die , patient TCC AVG assume warfarin maintain target INR 1.8 2.5 . Six wash consecutive session carry start study Fresenius FX8 Helyxone® , patient underwent HD , FX 80 Helyxone® , patient underwent hemodiafiltration ( HDF ) . After wash period , fresh whole blood serum sample draw start dialysis , midweek HD session 4 consecutive week . For patient mean value 4 blood sample consider . All patient continue HD HDF FX8 FX 80 Helyxone® whole study period.In order estimate normal range parameter evaluate , 60 anonymous healthy volunteer also submit assay .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<criteria>All patient recruit study infection thrombosis free almost 6 month . No patient include autoimmune disease , hepatic failure , diabetes malignancy . Patients administer ACE inhibitor , angiotensin receptor antagonist , antiinflammatory immunosuppressive drug . All patient residual GFR &lt; 5 ml/min . The vascular access consider place least 6 month . Patients recirculating vascular access &gt; 10 % exclude study . Patients acute cardiovascular accident last 15 day start study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>AVF</keyword>
	<keyword>AVG</keyword>
	<keyword>TCC</keyword>
	<keyword>inflammation</keyword>
	<keyword>monocite senescence</keyword>
</DOC>